RVL Pharmaceuticals

RVL Pharmaceuticals EBIT

The EBIT of RVL Pharmaceuticals (RVLPQ) as of Nov 16, 2026 is -45.68 M USD. In the previous year, EBIT was -80.51 M USD — a change of -43.26% (higher).

EBIT

-45.68 MUSD

YoY

-43.26%

Last updated:

In 2022, RVL Pharmaceuticals's EBIT was -45.68 M USD, a -43.26% increase from the -80.51 M USD EBIT recorded in the previous year.

The RVL Pharmaceuticals EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2021
-80.51 M USD
Jan 1, 2022
-45.68 M USD
Jan 1, 2023 (e)
-52.00 M USD
Jan 1, 2024 (e)
-34.79 M USD
Jan 1, 2025 (e)
-19.61 M USD
Jan 1, 2026 (e)
55.09 M USD
Jan 1, 2027 (e)
87.31 M USD
Jan 1, 2028 (e)
152.96 M USD
The RVL Pharmaceuticals EBIT history
YEAREBITYoY
est152.96 MUSD+75.18%
est87.31 MUSD+58.48%
est55.09 MUSD-381.00%
est-19.61 MUSD-43.64%
est-34.79 MUSD-33.09%
est-52.00 MUSD+13.83%
-45.68 MUSD-43.26%
-80.51 MUSD+30.40%
-61.74 MUSD-1,668.65%
3.94 MUSD-103.99%
-98.54 MUSD+89.25%
-52.07 MUSD+62.47%
-32.05 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RVL Pharmaceuticals Revenue

RVL Pharmaceuticals Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
17.50 M USD
-80.51 M USD
-82.85 M USD
Jan 1, 2022
49.72 M USD
-45.68 M USD
-51.69 M USD
Jan 1, 2023 (e)
0.00 USD
-52.00 M USD
0.00 USD
Jan 1, 2024 (e)
0.00 USD
-34.79 M USD
0.00 USD
Jan 1, 2025 (e)
76.30 M USD
-19.61 M USD
-28.97 M USD
Jan 1, 2026 (e)
171.50 M USD
55.09 M USD
56.82 M USD
Jan 1, 2027 (e)
226.50 M USD
87.31 M USD
92.47 M USD
Jan 1, 2028 (e)
291.28 M USD
152.96 M USD
133.11 M USD

RVL Pharmaceuticals Margins

RVL Pharmaceuticals stock margins

The RVL Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RVL Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RVL Pharmaceuticals.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
79.33 %
-460.03 %
-473.40 %
Jan 1, 2022
80.98 %
-91.87 %
-103.96 %
Jan 1, 2023 (e)
80.98 %
- %
0.00 %
Jan 1, 2024 (e)
80.98 %
- %
0.00 %
Jan 1, 2025 (e)
80.98 %
-25.70 %
-37.96 %
Jan 1, 2026 (e)
80.98 %
32.12 %
33.13 %
Jan 1, 2027 (e)
80.98 %
38.55 %
40.83 %
Jan 1, 2028 (e)
80.98 %
52.51 %
45.70 %

RVL Pharmaceuticals Stock analysis

What does RVL Pharmaceuticals do? Osmotica Pharmaceuticals PLC is a global pharmaceutical company based in Dublin, Ireland. It was founded in 2008 and focuses on the development and marketing of specialized pharmaceutical products for the treatment of neurological and psychiatric disorders, as well as behavioral disorders. The company is divided into three business segments: the Commercial Part, the Branded Part, and the Trident Part. The Commercial Part is responsible for marketing generic pharmaceuticals and other specialty products in the USA and Canada. This includes products such as Venlafaxine ER for the treatment of depression and the Parkinson's medication Apomorphine. The Branded Part is responsible for the development and marketing of its own products. This includes products such as Osmolex ER for the treatment of Parkinson's and akathisia, as well as Ontinua ER for the treatment of fibromyalgia and neuropathies. The Trident Part of the company focuses on the development of novel ophthalmology products and other specialty products for the global market. The company has a strong commitment to clinical research and development, particularly in the development of new products for use in neurology and psychiatry. Osmotica holds a number of patents for its products and has a range of products in various stages of clinical development. The success of Osmotica is based on its business model, which relies on ongoing innovation through research and development, as well as a strong distribution network for its products. Thanks to its broad product portfolio and global presence, the company is well positioned for further growth and the expansion into new markets in the future. Overall, Osmotica Pharmaceuticals PLC is an emerging pharmaceutical company with a strong focus on the development of specialized products for neurological and psychiatric disorders, as well as behavioral disorders. The company has a broad product portfolio and is well positioned for future growth. RVL Pharmaceuticals is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing RVL Pharmaceuticals's EBIT

RVL Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of RVL Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

RVL Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in RVL Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about RVL Pharmaceuticals stock

EBIT of RVL Pharmaceuticals is -45.68 M USD in 2022.

EBIT of RVL Pharmaceuticals changed from -80.51 M USD to -45.68 M USD, representing a -43.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT RVL Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's RVL Pharmaceuticals historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — RVL Pharmaceuticals

All Key Metrics — RVL Pharmaceuticals